[go: up one dir, main page]

MX2012006434A - Procesos para la preparacion de deferasirox, y polimorfos de deferasirox. - Google Patents

Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.

Info

Publication number
MX2012006434A
MX2012006434A MX2012006434A MX2012006434A MX2012006434A MX 2012006434 A MX2012006434 A MX 2012006434A MX 2012006434 A MX2012006434 A MX 2012006434A MX 2012006434 A MX2012006434 A MX 2012006434A MX 2012006434 A MX2012006434 A MX 2012006434A
Authority
MX
Mexico
Prior art keywords
deferasirox
processes
preparation
polymorphs
present
Prior art date
Application number
MX2012006434A
Other languages
English (en)
Inventor
Ehud Marom
Michael Mizhiritskii
Shai Rubnov
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2012006434A publication Critical patent/MX2012006434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a procesos para la preparación de deferasirox, un quelante de hierro oral desarrollado para tratar la sobrecarga de hierro debido a, por ejemplo múltiples transfusiones sanguíneas. La presente invención adicionalmente proporciona nuevos pseudopolimorfos de deferasirox y una nueva forma amorfa de deferasirox, procesos para su preparación, así como también composiciones farmacéuticas que comprenden los mismos, y uso de los mismos en el tratamiento de sobrecarga de hierro.
MX2012006434A 2009-12-07 2010-01-28 Procesos para la preparacion de deferasirox, y polimorfos de deferasirox. MX2012006434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26709609P 2009-12-07 2009-12-07
PCT/IL2010/000074 WO2011070560A1 (en) 2009-12-07 2010-01-28 Processes for the preparation of deferasirox, and deferasirox polymorphs

Publications (1)

Publication Number Publication Date
MX2012006434A true MX2012006434A (es) 2012-07-30

Family

ID=44145166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006434A MX2012006434A (es) 2009-12-07 2010-01-28 Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.

Country Status (9)

Country Link
US (1) US8772503B2 (es)
EP (1) EP2509423B1 (es)
JP (1) JP2013512893A (es)
CN (1) CN102638985A (es)
AU (1) AU2010329487A1 (es)
BR (1) BR112012013710A2 (es)
CA (1) CA2781821A1 (es)
MX (1) MX2012006434A (es)
WO (1) WO2011070560A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2964659T3 (da) * 2013-03-06 2017-11-27 Biocon Ltd Fremgangsmåde til fremstilling af deferasirox
WO2014136062A2 (en) * 2013-03-06 2014-09-12 Biocon Limited Process for the preparation of deferasirox
CN104098519B (zh) * 2013-04-08 2018-08-21 江苏豪森药业集团有限公司 地拉罗司的精制方法
CN103396373B (zh) * 2013-07-22 2015-02-04 江苏奥赛康药业股份有限公司 地拉罗司的制备方法及其中间体化合物
CN103554040B (zh) * 2013-11-08 2015-12-02 南京靖龙药物研发有限公司 一种地拉罗司衍生物的制备方法
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
MA43271A (fr) * 2015-06-17 2018-09-26 Dispersol Technologies Llc Formulations améliorées de déférasirox et leurs procédés de fabrication
WO2017019581A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Process for making phosphorus-containing nucleoside prodrug compounds
CN108456148B (zh) * 2018-05-09 2020-09-25 陕西理工大学 N-(3,4,5-三羟基苯甲酰)-3,4,5-三羟基苯甲酰胺及其制备方法与应用
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法
CN118239902B (zh) * 2024-03-08 2024-09-17 健尔圣(珠海)医药科技有限公司 一种铁离子螯合剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2123897A5 (es) 1971-02-04 1972-09-15 Rhone Poulenc Sa
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
MY110249A (en) * 1989-05-31 1998-03-31 Univ Florida State Method for preparation of taxol using beta lactam
TW226993B (es) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
RU2468015C2 (ru) 2006-11-29 2012-11-27 Новартис Аг Полиморфные формы деферасирокса (icl670a)
WO2008094617A2 (en) 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of deferasirox
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox

Also Published As

Publication number Publication date
CA2781821A1 (en) 2011-06-16
AU2010329487A1 (en) 2012-06-14
EP2509423B1 (en) 2016-01-27
US20120245361A1 (en) 2012-09-27
EP2509423A1 (en) 2012-10-17
JP2013512893A (ja) 2013-04-18
BR112012013710A2 (pt) 2015-09-15
EP2509423A4 (en) 2013-07-31
CN102638985A (zh) 2012-08-15
US8772503B2 (en) 2014-07-08
WO2011070560A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
MX2012006434A (es) Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.
IN2012DN00971A (es)
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
NZ708928A (en) Mannose derivatives for treating bacterial infections
IN2012DN02805A (es)
PH12017501038A1 (en) Novel radioimmunoconjugates and uses thereof
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
IN2012DN01233A (es)
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
GB201118656D0 (en) New compounds
PH12013502411A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
MY164731A (en) Compound
MX2012000565A (es) Derivados de triterpeno tipo lupeol como antivirales.
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
IN2012DN01292A (es)
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
IL194353A0 (en) Lysobactin amides
IN2014DN09437A (es)
MX2011011062A (es) Derivados de tioxanteno para el tratamiento de enfermedades infecciosas.
UA104102C2 (en) α-CRYSTALLINE FORM OF CARBABENZPYRIDE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal